Wells Fargo Maintains Overweight on Acelyrin, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Acelyrin (NASDAQ:SLRN) and raised the price target from $13 to $15.
October 16, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has maintained an Overweight rating on Acelyrin and increased the price target from $13 to $15, indicating a positive outlook.
The increase in price target from $13 to $15 by Wells Fargo suggests a positive outlook for Acelyrin, likely leading to a short-term increase in stock price. The Overweight rating indicates confidence in the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100